Skip to main content

Table 3 Clinical characteristics, drug concentrations and genotyping of Plasmodium vivax among patients with recurrences

From: A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India

  Patient 1 Patient 2 Patient 3 Patient 4
Age (years) 22 57 20 60
Gender Male Male Male Male
Weight (kg) 84.7 83 70 60
Body mass index 28.40 29.76 25.40 23.73
Past h/o malaria Yes No Yes No
Clinical phenotype of index episode Non-severe Non-severe Non-severe Non-severe
Schizonticidal drug Chloroquine Artesunate + Doxycycline Chloroquine Chloroquine
Regimen of PQ High Low Low High
Actual dose of PQ received (mg/day) 45.0 22.5 15.0 30.0
Actual dose of PQ received (mg/kg) 0.53 0.27 0.21 0.50
Time to first recurrence (days) 105 100 93 80
Clinical phenotype of recurrent episode Non-severe Non-severe Non-severe Non-severe
Schizonticidal drug of recurrence Chloroquine Chloroquine Chloroquine Chloroquine
PQ dose during recurrent episode (mg/day) 45.0 15.0 37.5 30.0
Drug levels during index episode
 PQ Level (µg/ml) 6.518 0.240 0.159 NA
 CPQ Level (µg/ml) 4.714 8.026 0.746 NA
Drug levels during recurrence
 PQ Level (µg/ml) 0.267 NA 0.399 NA
 CPQ Level (µg/ml) 3.873 NA 0.536 NA
Amplicon sizes (MS7)
 Initial infection 342 351 351 345
 Recurrent infection 342 351 351 345
Amplicon sizes (MS10)
 Initial infection 263 254 290 290
 Recurrent infection 263 254 290 290
  1. NA not available